Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Hypertens Res
2019 Nov 01;4211:1683-1691. doi: 10.1038/s41440-019-0301-z.
Show Gene links
Show Anatomy links
Melatonin attenuates renal sympathetic overactivity and reactive oxygen species in the brain in neurogenic hypertension.
Nishi EE
,
Almeida VR
,
Amaral FG
,
Simon KA
,
Futuro-Neto HA
,
Pontes RB
,
Cespedes JG
,
Campos RR
,
Bergamaschi CT
.
???displayArticle.abstract???
Sympathetic overactivation contributes to the pathogenesis of both experimental and human hypertension. We have previously reported that oxidative stress in sympathetic premotor neurons leads to arterial baroreflex dysfunction and increased sympathetic drive to the kidneys in an experimental model of neurogenic hypertension. In this study, we hypothesized that melatonin, a potent antioxidant, may be protective in the brainstem regions involved in the tonic and reflex control of blood pressure (BP) in renovascular hypertensive rats. Neurogenic hypertension was induced by placing a silver clip (gap of 0.2 mm) around the left renal artery, and after 5 weeks of renal clip placement, the rats were treated orally with melatonin (30 mg/kg/day) by gavage for 15 days. At the end of melatonin treatment, we evaluated baseline mean arterial pressure (MAP), renal sympathetic nerve activity (rSNA), and the baroreflex control of heart rate (HR) and rSNA. Reactive oxygen species (ROS) were detected within the brainstem regions by dihydroethidium staining. Melatonin treatment effectively reduced baseline MAP and sympathoexcitation to the ischemic kidney in renovascular hypertensive rats. The baroreflex control of HR and rSNA were improved after melatonin treatment in the hypertensive group. Moreover, there was a preferential decrease in ROS within the rostral ventrolateral medulla (RVLM) and the nucleus of the solitary tract (NTS). Therefore, our study indicates that melatonin is effective in reducing renal sympathetic overactivity associated with decreased ROS in brainstem regions that regulate BP in an experimental model of neurogenic hypertension.
Allegra,
The chemistry of melatonin's interaction with reactive species.
2003, Pubmed
Allegra,
The chemistry of melatonin's interaction with reactive species.
2003,
Pubmed
Berenguer,
Role of renin-angiotensin system in the impairment of baroreflex control of heart rate in renal hypertension.
1991,
Pubmed
Bergamaschi,
Role of the rostral ventrolateral medulla in maintenance of blood pressure in rats with Goldblatt hypertension.
1995,
Pubmed
Booth,
Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep.
2015,
Pubmed
Booth,
Reinnervation following catheter-based radio-frequency renal denervation.
2015,
Pubmed
DiBona,
Neural control of renal function.
1997,
Pubmed
Erşahin,
Melatonin improves cardiovascular function and ameliorates renal, cardiac and cerebral damage in rats with renovascular hypertension.
2009,
Pubmed
Garcia,
The antioxidant effects of green tea reduces blood pressure and sympathoexcitation in an experimental model of hypertension.
2017,
Pubmed
Girouard,
Treatment by n-acetylcysteine and melatonin increases cardiac baroreflex and improves antioxidant reserve.
2004,
Pubmed
Girouard,
Vasorelaxant effects of the chronic treatment with melatonin on mesenteric artery and aorta of spontaneously hypertensive rats.
2001,
Pubmed
Katholi,
Renal nerves in the pathogenesis of hypertension in experimental animals and humans.
1983,
Pubmed
Katholi,
Importance of the renal nerves in established two-kidney, one clip Goldblatt hypertension.
1982,
Pubmed
Kishi,
Overexpression of eNOS in RVLM improves impaired baroreflex control of heart rate in SHRSP. Rostral ventrolateral medulla. Stroke-prone spontaneously hypertensive rats.
2003,
Pubmed
Li,
Oxygen-derived free radicals contribute to baroreceptor dysfunction in atherosclerotic rabbits.
1996,
Pubmed
Manchester,
Melatonin: an ancient molecule that makes oxygen metabolically tolerable.
2015,
Pubmed
Navar,
Unraveling the Mystery of Goldblatt Hypertension.
1998,
Pubmed
Nishi,
Chronic antioxidant treatment improves arterial renovascular hypertension and oxidative stress markers in the kidney in Wistar rats.
2010,
Pubmed
Nishi,
Losartan reduces oxidative stress within the rostral ventrolateral medulla of rats with renovascular hypertension.
2013,
Pubmed
Nishi,
Renal denervation reduces sympathetic overactivation, brain oxidative stress, and renal injury in rats with renovascular hypertension independent of its effects on reducing blood pressure.
2019,
Pubmed
Ohashi,
The pivotal role of melatonin in ameliorating chronic kidney disease by suppression of the renin-angiotensin system in the kidney.
2019,
Pubmed
Oliveira-Sales,
Oxidative stress in the sympathetic premotor neurons contributes to sympathetic activation in renovascular hypertension.
2009,
Pubmed
Oliveira-Sales,
Kidney-induced hypertension depends on superoxide signaling in the rostral ventrolateral medulla.
2010,
Pubmed
Oskutyte,
Rostral parvicellular reticular formation neurons projecting to rostral ventrolateral medulla receive cardiac inputs in anesthetized rats.
2006,
Pubmed
Paulis,
Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind.
2007,
Pubmed
Pechanova,
Peripheral and central effects of melatonin on blood pressure regulation.
2014,
Pubmed
Qiu,
Aerobic exercise enhanced endothelium-dependent vasorelaxation in mesenteric arteries in spontaneously hypertensive rats: the role of melatonin.
2018,
Pubmed
Ramos,
Ischemic brain injury: New insights on the protective role of melatonin.
2017,
Pubmed
Reiter,
Melatonin as an antioxidant: physiology versus pharmacology.
2005,
Pubmed
Reiter,
Delivery of pineal melatonin to the brain and SCN: role of canaliculi, cerebrospinal fluid, tanycytes and Virchow-Robin perivascular spaces.
2014,
Pubmed
Roberie,
What is the prevalence of resistant hypertension in the United States?
2012,
Pubmed
Rodriguez,
Regulation of antioxidant enzymes: a significant role for melatonin.
2004,
Pubmed
Russo,
Anti-oxidant status and lipid peroxidation in patients with essential hypertension.
1998,
Pubmed
Simko,
Melatonin as a potential antihypertensive treatment.
2007,
Pubmed
Simko,
Elevated heart rate and nondipping heart rate as potential targets for melatonin: a review.
2016,
Pubmed
Tomaszewski,
High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis.
2014,
Pubmed
de Oliveira-Sales,
Upregulation of AT1R and iNOS in the rostral ventrolateral medulla (RVLM) is essential for the sympathetic hyperactivity and hypertension in the 2K-1C Wistar rat model.
2010,
Pubmed
